# Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

> **NCT00776984** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 453 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** tiotropium 5mcg/day
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00776984
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-07
- **Final completion:** —
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2014-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776984, "Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00776984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*